Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis.

Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Sripongpun, P. n., Mannalithara, A. n., Kwo, P. Y., Kim, W. R. 2019

Abstract

Tenofovir alafenamide (TAF) is the latest agent approved for chronic hepatitis B virus (HBV) treatment. In its registrations trials, TAF demonstrated better renal safety and improvement in alanine aminotransferase (ALT) activities compared with tenofovir disoproxil fumarate (TDF).1-3 However, data are scarce regarding these outcomes in liver transplantation (LTx) recipients.4 In this study, we determine effects of switching from other antivirals to TAF on ALT and renal function in LTx recipients.

View details for DOI 10.1016/j.cgh.2019.05.057

View details for PubMedID 31271737